Management of Chronic Myeloid Leukemia with Sever COVID 19: A Case Report
DOI:
https://doi.org/10.3889/oamjms.2020.5143Keywords:
CML, Covid-19, TKIAbstract
Coronavirus disease-19 (COVID-19) is a pandemic viral disease that can cause devastating complications such as acute respiratory disease, especially in patients with comorbidities. We do not know yet full pictures of this disease, especially in hematological malignancies. Here, we present management of a 57-year-old male with chronic phase chronic myeloid leukemia, tested positive for COVID-19, then complicated with acute respiratory distress syndrome.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. https://doi.org/10.1001/jama.2020.2648 PMid:32091533
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: A systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-5. PMid:32173574
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol. 2020;21(3):335-7. PMid:32066541
Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21:e181. PMid:32142621
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European leukemia net 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-84. PMid:32127639
Alshurafa A, Alkhatib M, Abou Kamar M, Yassin MA. Confirmed coronavirus disease-19 (COVID-19) in a male with chronic myeloid leukemia complicated by febrile neutropenia and acute respiratory distress syndrome. Case Rep Oncol. 2020;13(2):569-77. https://doi.org/10.1159/000508378
Wang D, Guo J, Yang Z, You Y, Chen Z, Chen S, et al. The first report of the prevalence of COVID-19 in chronic myelogenous leukemia patients in the core epidemic area of China: A multicentre. Cross Sectional Surv. Hematol. 2020;1:20034876.
Tanaka A, Nishikawa H, Noguchi S, Sugiyama D, Morikawa H, Takeuchi Y, et al. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J Exp Med. 2020;217(2):e20191009. PMid:31704808
Ureshino H, Shindo T, Kimura S. Role of cancer immunology in chronic myelogenous leukemia. Leuk Res. 2020;88:106273. PMid:31765938
Climent N, Plana M. Immunomodulatory activity of tyrosine kinase inhibitors to elicit cytotoxicity against cancer and viral infection. Front Pharmacol. 2019;10:1232. PMid:31680987
Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol. 2016;90(19):8924-33. https://doi.org/10.3389/fphar.2019.01232 PMid:27466418
Reinwald M, Boch T, Hofmann WK, Buchheidt D. Risk of infectious complications in hemato-oncological patients treated with kinase inhibitors. Biomark Insights. 2015;10(Suppl 3):55-68. https://doi.org/10.1128/jvi.01429-16 PMid:27127405
Avchaciov K, Burmistrova O, Fedichev PO. AI for the Repurposing of Approved or Investigational Drugs Against COVID. Available from: https://www.researchgate.net/publication/339998830_AI_for_the_repurposing_of_approved_or_investigational. [Last accessed on 2020 Mar].
Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D. COVID-19: Combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400-2. https://doi. org/10.1016/j.lfs.2020.117627 PMid:32113509
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):507-13. https://doi.org/10.1016/s1473-3099(20)30132-8 PMid:32007143
Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533-5. https://doi.org/10.1016/s0140-6736(20)30211-7 PMid:32203188
Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. COVID-19, cytokines and immunosuppression: What can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38(2):337-42. PMid:32202240
Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020;506:145-8. PMid:32178975
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. https://doi.org/10.1016/j.cca.2020.03.022 PMid:32192578
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20. https://doi.org/10.1016/ s0140-6736(20)30628-0
Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID- 19. Eur Heart J Cardiovasc Pharmacother. 2020;6(4):260-1. PMid:32352517
Mummery RS, Rider CC. Characterization of the heparin-binding properties of IL-6. J Immunol. 2000;165(10):5671-569. PMid:11067924
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Rasha Ibrahim, Georgios P. Chatzis, Mohamed A. Korayem, Mahmoud K. Mansour (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
